Press Releases December 9, 2024 AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer August 23, 2024 AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema December 11, 2023 AiViva BioPharma Completes Phase 1 / 2 Clinical Trial of AIV001 for Administration in Patients with Nonmelanoma Skin Cancer September 18, 2023 AiViva BioPharma Appoints Les Kaplan, to the Board of Directors August 30, 2023 AiViva BioPharma Appoints Jung-Chin (Rongjin), to the Board of Directors May 22, 2023 AiViva BioPharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema August 17, 2022 AiViva BioPharma Announces New Patent Received October 2, 2020 AiViva BioPharma Initiates Phase 1 / 2 Clinical Trial of AIV001 Nonmelanoma Skin Cancer June 25, 2020 AiViva BioPharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
